Lumos Pharma — Technical Presentation (November 2022)
55 slides from Lumos Pharma's technical presentation, Nov 14, 2022
Slide 1: Interim Analysis OraGrowtH210 & OraGrowtH212
1 Interim Analysis OraGrowtH210 & OraGrowtH212 November 14, 2022
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made
Slide 3: Investment Highlights
3 Investment Highlights Lead asset targeting children with growth disorders PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Positi
Slide 4: Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD
4 Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treatment inter
Slide 5: OraGrowtH210 Trial: Phase 2 Trial Evaluating Oral LUM-201 in Moderate PGHD
OraGrowtH210 Trial Phase 2 Trial Evaluating Oral LUM-201 in Moderate PGHD
Slide 6: LUM-201 Stimulates Natural Growth Hormone Secretion
6 LUM-201 Stimulates Natural Growth Hormone Secretion • LUM-201 is an oral GH secretagogue* • Acts on specific receptors in hypothalamus and pituitary to stimulate release of GH1 • Increases the amplitude of natural pulsatile GH secretion2,3 • LUM-201 stimulated GH release regulated by natural GH/IG
Slide 7: PEMs Enrich Trials for Patients Likely to Respond to LUM-201
7 PEMs Enrich Trials for Patients Likely to Respond to LUM-201 (PEM+) PEM-positive = PGHD patients with baseline IGF-1 > 30 ng/ml & stimulated GH ≥ 5 ng/ml 1 Bright 2021 JES HP-GH axis – hypothalamic pituitary growth hormone axis 2 Blum 2021 JES Responders Non-Responders ~ PEMs = Predictive Enrichme
Slide 8: OraGrowtH210 Trial: Phase 2 Trial in PGHD
8 OraGrowtH210 Trial: Phase 2 Trial in PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~40 trial sites US &
Slide 9: Historical Data for rhGH Growth Rates in Moderate PGHD Patients
9 Historical Data for rhGH Growth Rates in Moderate PGHD Patients rhGH 0204 rhGH GeNeSIS1 rhGH iPGHD2 rhGH KIGS3 0 4 8 12 16 20 n=3075 8.58 n=100 8.30 n=433 8.29 n=11 8.80 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) • GeNeSIS1, iPGHD2, and KIGS3 AHV from 12 months of rhGH • Merck 0204 AH
Slide 10: OraGrowtH210 Interim Analysis: AHV at 6 Months
10 OraGrowtH210 Interim Analysis: AHV at 6 Months (41 Subjects) • LUM-201 1.6 mg/kg/day cohort grew 8.6 cm/yr, in line with the expected rate of 8.3 cm/yr based on prior data • rhGH cohort grew at a much faster rate than expected or previously reported in moderate PGHD population • Cohort baseline d
Slide 11: LUM-201 Growth in Trial is Consistent with Historical Precedent
11 LUM-201 Growth in 210 Trial is Consistent with Historical Precedent The rhGH arm in 210 trial showed growth inconsistent with multiple historical studies in this PGHD population Sources: 1 Blum et al JES 2021, 2 Lechuga-Sancho et al JPEM 2009, 3 Ranke et al JCEM 2010, 4 Bright et al JES 2021. Con
Slide 12: OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms
12 OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms in Moderate PGHD Patient Population Unprecedented rhGH growth response in OraGrowtH 210 in moderate PGHD likely due to outlier & small sample size Expect larger N from fully enrolled dataset to reduce impact of growth outliers 1) Rose
Slide 13: OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms
13 OraGrowtH210 Trial rhGH Cohort Grew More than Historical Norms in Moderate PGHD Patient Population Unprecedented rhGH growth response in OraGrowtH 210 in moderate PGHD likely due to outlier & small sample size Expect larger N from fully enrolled dataset to reduce impact of growth outliers 1) Rose
Slide 14: Key Baseline Characteristics that Predict Better AHV With rhGH Treatment
14 Key Baseline Characteristics that Predict Better AHV With rhGH Treatment of PGHD Patients Historical data from multiple peer-reviewed scientific publications demonstrate the following metrics as key predictors of first-year growth • Baseline Age • Age is the top predictor of growth on treatment •
Slide 15: Baseline Characteristics by Cohort
15 LUM-201 0.8 mg Mean (SD) N=11 LUM-201 1.6 mg Mean (SD) N=10 LUM-201 3.2 mg Mean (SD) N=10 rhGH Mean (SD) N=10 Age (months) 95.5 (28.2) 99.3 (28.3) 96.1 (21.7) 90.3 (26.7) Height (cm) 113.8 (12.6) 114.6 (9.6) 113.8 (8.8) 111.6 (11.9) Height SDS -2.31 (0.32) -2.35 (0.62) -2.30 (0.48) -2.29 (0.43) M
Slide 16: Baseline Comparison of 1.6mg Arm to Control Arm
16 Baseline Comparison of 1.6mg Arm to Control Arm LUM-201 1.6 mg Mean (SD) N=10 rhGH Mean (SD) N=10 Age in months 99.3 (28.3) 90.3 (26.7) Height in cm 114.6 (9.6) 111.6 (11.9) Height SDS -2.35 (0.62) -2.29 (0.43) Min Height SDS -3.90 -3.07 IGF-1 SDS -1.17 (0.72) -1.37 (0.48) Max IGF-1 SDS -0.3 -0.7
Slide 17: Growth Outliers in the rhGH Cohort: Subjects under 5
17 Age (years) Growth Outliers in the rhGH Cohort: 2/3 Subjects under 5 Randomized to rhGH 1 Ranke, et al 2010 JCEM OraGrowtH210 youngest subjects in rhGH cohort at 6-months AHV P lines = Percentiles “Before” line marks height velocity before GH therapy First-year Growth on rhGH for Moderate PGHD KI
Slide 18: Baseline Characteristics by Cohort (Larger N)
18 LUM-201 0.8 mg Mean (SD) N=14 LUM-201 1.6 mg Mean (SD) N=15 LUM-201 3.2 mg Mean (SD) N=14 rhGH Mean (SD) N=15 Age (months) 99.1 (28.3) 98.4 (28.6) 92.9 (22.6) 94.1 (23.7) Height (cm) 115.1 (12.5) 114.6 (11.2) 112.4 (9.2) 113.4 (10.6) Height SDS -2.32 (0.3) -2.31 (0.5) -2.32 (0.4) -2.25 (0.4) Max
Slide 19: Baseline Comparison of rhGH Arm at N=15 and N=10
19 Baseline Comparison of rhGH Arm at N=15 and N=10 rhGH Mean (SD) N=15 rhGH Mean (SD) N=10 Age in months 94.1 (23.7) 90.3 (26.7) Height in cm 113.4 (10.6) 111.6 (11.9) Height SDS -2.25 (0.4) -2.28 (0.43) Max Height SDS -1.73 -1.73 IGF-1 SDS -1.32 (0.46) -1.37 (0.48) Max IGF-1 SDS -0.7 -0.7 MPH in c
Slide 20: Data: LUM-201 Demonstrates Durable Response to 9 Months
20 210 Data: LUM-201 Demonstrates Durable Response to 12 Months • LUM-201 growth rates consistent from 6 to 12 months • rhGH growth rates decline more from 6 to 12 months, narrowing the AHV ∆ between the arms at 12 months • A Phase 3 non-inferiority trial is expected to be a 12-month study in a much
Slide 21: OraGrowtH212 Trial: PK/PD Trial Evaluating Oral LUM-201 in PGHD
OraGrowtH212 Trial PK/PD Trial Evaluating Oral LUM-201 in PGHD
Slide 22: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD
22 • n = up to 24 • Open-label study • PGHD patients • rhGH-treatment naïve • Dosing to near-adult height • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endoge
Slide 23: OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months
23 OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months • OraGrowtH212 Trial results showed a similar growth rate to OraGrowtH210 Trial • Anticipate fully enrolled datasets and larger N from both trials to strengthen these results • Anticipate larger Phase 3 trial to further support the LUM- 201
Slide 24: OraGrowtH212 Data Demonstrate Durable Response
24 OraGrowtH212 Data Demonstrate Durable Response • OraGrowth212 data also demonstrate growth is durable out to 12 months • This separate study supports the narrowing of the AHV difference seen in the 210 trial as subjects approach 12 months on treatment • A Phase 3 non-inferiority trial is expected
Slide 25: OraGrowtH210 & OraGrowtH212 Interim Data Combined
25 OraGrowtH210 & OraGrowtH212 Interim Data Combined • Post-hoc analysis of combined data conducted to determine optimal dose for Phase 3 • Comparable mean AHVs for top 2 LUM-201 doses seen at 6,9, and 12 months • Combined interim data supports selection of 1.6 mg/kg/day dose for pivotal Phase 3 tri
Slide 26: Safety and Tolerability
Safety and Tolerability
Slide 27: Interim Safety and Tolerability Profile
27 Interim Safety and Tolerability Profile • We believe LUM-201 will demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials. • No meaningful safety signals to date o In laboratory values o In Advers
Slide 28: Financials
Financials
Slide 29: Lumos Pharma Financial Information as of September 30, 2022
29 Lumos Pharma Financial Information as of September 30, 2022 Values in USD Cash $73.7M Debt $0 Shares Outstanding 8.4M Cash Use in Q4 2022 $8.5-$9.5M Fiscal Year End December 31 LUMO Cash balance to support current operations into 2Q 2024, Beyond primary outcome data readouts for OraGrowtH210 and
Slide 30: Conclusions
Conclusions
Slide 31: Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD
31 Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treatment inte
Slide 32: Interim Analysis Supplemental Materials
Interim Analysis Supplemental Materials
Slide 33: Safety Profile at Interim Analysis for OraGrowtH210 Trial
33 Safety Profile at Interim Analysis for OraGrowtH210 Trial 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose* 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg ALL LUM-201 rhGH 34 mcg/kg N = 86 14 15 14 43 15 Number of AEs 29 31 45 38 114 21 Subjects with AE (%) 17
Slide 34: Specific AEs – No meaningful signal
34 Specific AEs – No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose* N=86 0.8 N=14 1.6 N=15 3.2 N=14 ALL N=43 rhGH N=15 Arthralgia 1 (1.2%) 1 (7.1%) 2 (13.3%) 2 (14.3%) 5 (11.6%) 1 (6.7%) Myalgia 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (
Slide 35: Specific AEs - No meaningful signal
35 Specific AEs - No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis PEM Dose N=86 0.8 N=14 1.6 N=15 3.2 N=14 ALL N=43 rhGH N=15 Asthma 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (7.1%) 1 (2.3%) 0 (0.0%) Hyperhydrosis 2 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.
Slide 36: Laboratory Shifts: No meaningful signal
36 * Percentages calculated based on subjects with both baseline and post-baseline assay data ** Bidirectional shifts diminish any concern Laboratory Shifts: No meaningful signal 66 subjects randomized to date with safety data available for 58 subjects at interim analysis* 0.8 mg/kg N=14 1.6 mg/kg N
Slide 37: Baseline Characteristics for Top Dose Cohorts in 210 and 212 Studies
37 Baseline Characteristics for Top Dose Cohorts in 210 and 212 Studies 210 1.6 mg/kg N=10 210 3.2 mg/kg N=10 212 1.6 mg/kg N=5 212 3.2 mg/kg N=5 Age (Mos) 99.3 96.1 93.6 91.0 Height SDS -2.35 -2.30 -1.99 -2.26 IGF-1 SDS -1.17 -1.39 -1.11 -0.83 Delta MPH 1.76 1.96 0.57 0.70 BA delay yr 1.91 2.19 1.5
Slide 38: Growth Outliers in the rhGH Cohort: Subjects under 5
38 Age (years) Growth Outliers in the rhGH Cohort: 2/3 Subjects under 5 Randomized to rhGH Ranke, et.al. 2010 JCEM OraGrowtH210 Top growers in rhGH cohort at 6-months AHV outlier P lines = Percentiles “Before” line marks height velocity before GH therapy
Slide 39: Ranke Model is the Gold Standard in Growth Prediction for GHD
39 Ranke Model is the Gold Standard in Growth Prediction for GHD PHV = 14.55 + [-1.37 X (ln max GH stim)] + (-0.32 X Age) + (0.32 X BWt SDS) + (-0.5457) + (-0.4 X HtSDS-MPH SDS) + (0.29 X Wt SDS) [-1.37 X (ln max GH stim)]• Parameter Rank 1st A measure of how GHD subject is by stim test value (-0.32
Slide 40: What does Ranke Model Predict about Growth in our Trial Cohorts?
40 What does Ranke Model Predict about Growth in our Trial Cohorts? Growth predicted using baseline characteristics of subjects enrolled in OraGrowtH210 • Our assessment is that the key baseline characteristics, particularly age, between cohorts are enough to bias the rhGH cohort towards more growth
Slide 41: What does Ranke Model Predict about Growth in our Trial Cohorts?
41 What does Ranke Model Predict about Growth in our Trial Cohorts? Growth predicted using baseline characteristics of subjects enrolled in OraGrowtH210 • 1.6 mg/kg cohort is aligned with Ranke model predictions at all time points • rhGH cohort grows faster than predicted likely due to outliers • Th
Slide 42: Additional Supplemental Materials
42 Additional Supplemental Materials
Slide 43: Management – Significant Clinical Development and Commercial Experience
43 Management – Significant Clinical Development and Commercial Experience Richard Hawkins Chairman & CEO Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biotechnology).
Slide 44: LUM-201 Program Pipeline
44 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial: Interim analysis obtained Primary outcome data 2H 2023 Long-term extension Proposed long-term extension study for OraGrowtH Trials PK/PD trial Ongoing PK/PD trial
Slide 45: PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market
45 PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market • Pediatric rhGH market projected to grow ~8% per year* • Well characterized market with established reimbursement mechanisms • Current SOC consists of daily injectables; expected to convert to weekly injectables • Pediatric rh
Slide 46: Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable
46 Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable 1 Initial Primary Research of PGHD Market conducted for Lumos by Triangle Insights. Physicians N = 20. Caregivers N = 9. 75% 25% Interview Question: If a daily oral secretagogue and a weekly rhGH injectable product were both
Slide 47: Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral
47 Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral 1 GlobalData EpiCast Report for Growth Hormone Deficiency Epidemiology forecast to 2026 2 Rosenfeld 2008 Endocrine Practice 3 Cutfield 2011 PLOS ONE • Inadequate secretion of growth hormone during childhood • Majority
Slide 48: Significant Prior Clinical Experience with LUM-201 – Both Pediatric and Adult
48 Significant Prior Clinical Experience with LUM-201 – Both Pediatric and Adult • Multiple trials were conducted by Merck prior to Lumos acquisition of LUM-201 in July 2018 • Six large-scale adult studies (n ~1,000) o In every adult indication, IGF-1 and/or GH levels were meaningfully increased fro
Slide 49: Study 020 Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201
49 Study 020 Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201 • Naïve PGHD, Study 020 o N=68; three arms o Placebo patients switched to rhGH at 6 months o Annualized growth shown for each arm • PEM-positive subset: o LUM-201 0.8 mg/kg not statistically different from rhGH o Dose respon
Slide 50: PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers
50 PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers PharmacodynamicsPharmacokinetics Dose response to 5.6 mg/kg PGHD dose equivalent* PD plateau possible ≥ 2.8 mg/kg PGHD dose equivalent* Higher LUM-201 doses produce higher plasma concentrations of LUM-201 & GH up to PD plateau PD
Slide 51: PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients
51 PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in PGHD Patients * Merck Study 020 patient subset. Cassorla, F. PEM Positive PEM Negative Patient A Patient B Patient C Baseline 6months Baseline 6months Baseline 6months IGF-1 (ng/ml) 182 231 53 72 17 15 Q20m 24h GH Mean (ng/ml) 3.4 6.3
Slide 52: More GH Released from LUM-201 Stim than from Standard Stim Test Agents
52 More GH Released from LUM-201 Stim than from Standard Stim Test Agents 0 2 4 6 8 10 12 GH to Standard GH Stimulation Tests (ng/mL) 2 4 6 8 20 40 60 80 G H t o S in g le D o s e L U M -2 0 1 ( n g /m L ) 68 children with growth hormone deficiency All had 2 standard GH stimulation tests • Standard
Slide 53: Exclusivity and Barriers with Orphan Designation and IP
53 Exclusivity and Barriers with Orphan Designation and IP With potential pediatric extensions, LUM-201 is eligible for: Plan to seek Orphan Drug Designation in Japan Use of LUM-201 in PGHD and other GHD indications based on PEM strategy Patents for LUM-201 in GHD with protection through 2036 • Pate
Slide 54: Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD)
54 • n = 10 • Adult NAFLD subjects with relative GH/IGF-1 deficiency • Open-label • Single-site pilot study • 6-month dosing Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD) Mass General Investigator-Initiated Phase 2 Pilot Trial Primary Objective: • Determine changes in intra- hep
Slide 55: LUM-201 Deal Terms
55 LUM-201 Deal Terms *Milestone figures are maximum, may be less depending on development stage achieved and total net sales up to $1B Partner Upfront Payment Development Milestones* Sales Milestones* Worldwide Sales Royalties, Combined Ammonett $3.5M $17M first indication $14M second indication $5
Lumos Pharma — Technical Presentation (November 2022) on 6ix